Goldman Sachs reiterated coverage on Quotient with a new price target

12/3/21 9:07:16 AM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $3.50 from $4.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$QTNT

Date	Price Target	Rating	Analyst
12/3/2021	$4.00 → $3.50	Neutral	Goldman Sachs
8/6/2021	$5.00 → $4.50	Neutral	Goldman Sachs